Republic of Korea-based Samsung Bioepis announced on Tuesday that the FDA has accepted for review the company’s Biologics License Application (BLA) for SB3, a proposed trastuzumab biosimilar, referenced on Herceptin. If the FDA approves SB3, the drug will be commercialized in the US by Merck.
Republic of Korea-based Samsung Bioepis announced on Tuesday that the FDA has accepted for review the company’s Biologics License Application (BLA) for SB3, a proposed trastuzumab biosimilar, referenced on Herceptin. If the FDA approves SB3, the drug will be commercialized in the US by Merck.
In November 2017, Samsung Bioepis gained the European Commission’s marketing authorization for SB3, making the drug the first biosimilar trastuzumab to be approved in the European Union. The company will sell the drug as Ontruzant in the European Union and in the European Economic Area member states of Norway, Iceland, and Liechtenstein. Also in November, the company gained the Republic of Korea’s clearance to market SB3; in the Korean marketplace, the drug will be sold as Samfenet. Samsung Bioepis’ regulatory wins follow the company’s June 2017 announcement of positive data from a phase 3 study in patients with newly diagnosed with stage II to stage III primary breast cancer, as well as 1-year data announced in September.
If approved by the FDA, SB3 will compete not only with the reference Herceptin—which analysts believe could earn Roche subsidiary Genentech up to $6.4 billion in 2018—but also with Ogivri, Mylan—Biocon’s recently FDA-approved biosimilar trastuzumab. While Roche has reportedly reached an undisclosed agreement with Mylan concerning the launch of Ogivri in the US marketplace, Roche has vigorously defended its patents covering the reference Herceptin in the United States; Roche recently filed a lawsuit against another biosimilar developer, Pfizer, seeking to prevent a launch of a biosimilar trastuzumab in the US marketplace. (Although Pfizer has not announced submission of a BLA to the FDA, it has released positive data showing noninferiority of its PF-05280014 to the EU-licensed reference Herceptin.)
Samsung Bioepis reports a number of other biosimilar products in its product pipeline. The company is developing the following: SB4, etanercept (referenced on Enbrel); SB2, infliximab (referenced on Remicade); SB5, adalimumab (referenced on Humira); SB9, insulin glargine (referenced on Lantus); and SB8, bevacizumab (referenced on Avastin).
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.